The Efficacy of Adjunctive Use of Ondansetron in Patients With Sepsis and Septic Shock
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Sepsis is a systemic inflammatory response that has deleterious effects and considered the
leading cause of death in critically ill patients 1 . One of the hallmarks of severe sepsis
is the progressive, injurious inflammatory response to infection, mediated by the excessive
release of inflammatory mediators and consequently, associated with multiple organs damage 2
. Various studies have demonstrated that adverse outcomes in sepsis patients are closely
related to the development of myocardial dysfunction 3 . The mortality of sepsis combined
with cardiac functional insufficiency has increased significantly to 70%-90% 4 . Therefore,
targeting cardiac insufficiency and heart injury may represent a novel treatment strategy.
Several reports documented critical involvement of serotonin 5-hydroxytryptamine in the
pathogenesis of sepsis. The aim of the current study is to evaluate the efficacy of
ondansetron adjuvant use in patients with sepsis and septic shock.